ous transplant. We report the treatment of a patient with relapsed common ALL with a second BMT from an unrelated donor, in order to contribute to the further evaluation A second bone marrow transplant might be considered as an option in patients with leukemia relapsing after of unrelated donors as the source of second BMT. bone marrow transplantation. We report the successful treatment of a patient with relapsed ALL with a second BMT from the same unrelated donor. We evaluated the Materials and methods usefulness of an unrelated donor as the source of the second BMT in this clinical setting. The conditioning regimen for the first transplantation consisted of BU First transplant and CY while fractionated TBI and CY were used for the second BMT. Acute skin GVHD, grade III which A 24-year-old patient with ALL was first diagnosed in October 1994, immunophenotype cALL (CD10 + , CD19 + , developed after second BMT, was successfully treated with the use of a new immunosuppressive drug, myco-CD34 + , HLA-DR + , TdT + ), Ph chromosome negative. He was treated with induction therapy according to the German phenolate mofetil. Hemorrhagic cystitis and a CMV infection developed as complications during the second ALL protocol 12 and was in CR for 12 months. He relapsed in November 1995 and was refractory to further chemo-BMT and were successfully treated. The patient was alive and well after the second BMT with limited therapy. The patient was admitted to our hospital for BMT. Conditioning for the first BMT consisted of BU 4 mg/kg chronic skin GVHD up to day +170. Keywords: second bone marrow transplant; unrelated p.o. in divided doses daily for 4 days, from day −7 to day −4 (total dose 16 mg/kg) and CY 60 mg/kg once daily i.v. bone marrow transplant; acute leukemia; GVHD; preparative regimen on days −3 and −2 (total dose 120 mg/kg). An HLA-identical volunteer unrelated donor marrow was infused on day 0 (1 day after the last CY dose). GVHD prophylaxis for the initial transplant consisted of CsA 5 mg/kg starting on Relapse of primary leukemia after BMT occurs in 20-80% day −3, MTX at days +1 and +3, +6 in doses of 15 mg/m 2 of patients.
of patients. 1, 2 Relapse rate depends upon the diagnosis and and 10 mg/m 2 , respectively. From day +7 the patient phase of disease at the time of BMT. 3, 4 Recently, it has received prednisolone at a dose of 0.5 mg/kg. He did not been shown that patients transplanted in relapse or after develop any sign of drug toxicity. The total number of primary induction failure have a significantly higher risk of infused unrelated bone marrow cells was 2.74 × 10 10 leukemic relapse than those transplanted during remission.
5 mononucleated cells. The number of CD34 + cells, determThe optimum management of relapse after first BMT, ined as already described 13 was 4.14 × 10 6 /kg. A total dose including whether to employ salvage therapy and/or second of infused CFU-GM determined by methylcellulose culture BMT, remains unresolved.
6,7 Most of the recently published assay 14 was 13.70 × 10
6
. Sustained engraftment with an literature describes the use of the same HLA-identical sibabsolute neutrophil count Ͼ500/l occurred on day +21. ling as the source of second transplant. [8] [9] [10] Recently, the The patient had no complications and was released from outcome of a second BMT in 23 patients receiving matched hospital on day +36 after BMT in CR with a normal differsibling or unrelated bone marrow has been published. 
Second transplant Chimerism studies
Quantitative monitoring of mixed chimerism after BMT The patient experienced an early relapse of ALL on day was performed by using PCR-short tandem repeat loci sys-+141 after the first BMT. Microscopic examination of pertem. 15 Briefly, DNA was extracted from buffy coat from ipheral blood at relapse showed a leukocyte count of 10 ml of peripheral blood anticoagulated with EDTA using 4500/l with 30% blasts immunophenotyped as CD10 + , the Quiam Blood Kit (Qiagen, Hilden, Germany). PCR CD19 + , HLA-DR + , CD34 + . Donor hemopoietic cell amplification was performed in an 9600 DNA thermal engraftment after BMT was found to be 40.9% at the time cycler system (Perkin Elmer, Foster City, CA, USA) using of relapse. Since the patient was in excellent clinical con-100-500 ng of genomic DNA, 5-10 pmol of each primer dition and additional conventional chemotherapy rarely and 0.5 units polymerase (Appligene-Oncor, Illkirsch, results in cure, a second BMT was offered using the same France). PCR products were analyzed together with an unrelated donor with the aim of obtaining long-term leukeinternal standard in the same lane of a standard 6% polymia-free survival. Conditioning for the second BMT conacrylamide denaturing sequencing gel. sisted of CY 60 mg/kg once daily i.v. on days −6 and −5 and TBI to a total dose of 13.5 Gy from days −4 to −2. Unrelated donor marrow from the same donor was infused Results with a total number of 1.66 × 10 10 mononuclear cells. The number of CD34 + cells was 2.28 × 10 6 /kg while the total Hematological and blood biochemical parameters of the dose of infused CFU-GM was 6.9 × 10 6 . GVHD prophypatient at first and second BMT are presented in Table 1 . laxis consisted of CsA 5 g/kg from day −3 and 0.5 mg/kg Sustained engraftment was promptly achieved and the hemprednisolone from day +7. Sustained engraftment was achiatological parameters were normal on day +30 after BMT. eved on day +20. Two weeks after BMT infusion, the
The interval between the first and second BMT was 6 patient developed hemorrhagic, polyoma virus-positive cysmonths and 2 days. Our patient developed acute GVHD, titis. In addition, he developed acute GVHD affecting skin grade III of the skin and eyes after the second BMT. He and eyes, grade III. Prednisolone therapy was increased.
responded to treatment with MMF in addition to prednisoHowever, acute GVHD worsened. A new immunosuppreslone and CsA. sive drug, mycophenolate mofetil (MMF) was administered at a dose of 2.0 g daily. He was tested for CMV antigenemia and found to be positive on day +34; therefore, therapy Discussion with gancyclovir was started. Morphological examination revealed a hypocellular bone marrow with decreased megakaryocytopoiesis which may be explained by the com-A second BMT is one of the treatment modalities for leukemia relapsing after BMT. Data published to date demonbination of gancyclovir and mycophenolate mofetil therapy. Donor hemopoietic engraftment was 100% at days 30, 60, strate high BMT-related mortality and relapse rates with an overall disease-free survival rate of 12-38%. 11 Most of the 90, 120 and 150 after second BMT. Protocols used in this study and consent were approved by the IRB of the Clinic second BMTs were performed using the same marrow donor. The experience using an unrelated donor as the of BMT and Hematology/Oncology. The procedure, as well as the risks and benefits were explained in detail to the source of cells for second BMT requires further evaluation. Our observation presented here revealed that a second BMT patient and donor.
